Further experience in treating patients with hepatocellular carcinoma in Uganda
Further experience in treating patients with hepatocellular carcinoma in Uganda
复制标题
乌干达治疗肝细胞癌患者的进一步经验
DOI：
10.1002/1097-0142(19801215)46:12
复制
发表时间：
1980
期刊：
影响因子：
6.2
通讯作者：
S. Kyalwazi
中科院分区：
文献类型：
--
作者：
C. Olweny;E. Katongole‐Mbidde;S. Bahendeka;D. Otim;Jusua Mugerwa;S. Kyalwazi
139例组织学证实的肝细胞癌（HC）患者在乌干达癌症研究所接受治疗。这些患者相当年轻，似乎比欧洲和北美的丙型肝炎患者有更多的晚期疾病。在99例可评估的患者中，50例接受静脉注射阿霉素；其中44%的患者有反应，10%的患者有完全反应。动脉注射阿霉素可将有效率提高到75%，但这可能仅仅是患者选择的反映。阿霉素与其他药物（二氯甲氨蝶呤、5 -氮扎胞苷、瑞唑环和环磷酰胺）合用没有提高其治疗效果。阿霉素与二氯甲氨蝶呤联用时观察到的甲胎蛋白反应曲线提示两种药物之间可能存在拮抗作用。肝动脉结扎（HAL）是一种简便易行的姑息治疗方法，其有效率与静脉注射阿霉素相似。然而，HAL后给予阿霉素倾向于改善反应率和生存率。观察到的症状主要是骨髓抑制，胃肠道紊乱，脱发，皮肤和粘膜色素沉着。
One hundred and thirty nine patients with histologically proven hepatocellular carcinoma (HC) were admitted to the Uganda Cancer Institute for treatment. The patients were considerably younger and seemed to have more advanced disease than HC patients in Europe and in North America. Of the 99 evaluable patients, 50 received Adriamycin intravenously; of these, 44% responded, with 10% achieving complete responses. Intraarterial Adriamycin tended to increase the response rate to 75%, but this may be merely a reflection of patient selection. Combination of Adriamycin with other drugs (dichloromethotrexate, 5‐azacytidine, Rezoxane and cyclophosphamide) did not enhance its therapeutic effectiveness. The alphafetoprotein response curves observed when Adriamycin was combined with dichtoromethotrexate suggested possible antagonisms between the two drugs. Hepatic artery ligation (HAL) is a good and simple palliative procedure with response rates similar to i.v. Adriamycin. However, the administration of Adriamycin after HAL tended to improve on response rates and survival. The toridties observed were mainly myelosuppression, gastrointestinal disturbance, alopecia, and hyperpigmentation of the skin and mucous membranes.